1. Home
  2. SNGX vs AUUD Comparison

SNGX vs AUUD Comparison

Compare SNGX & AUUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.38

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Logo Auddia Inc.

AUUD

Auddia Inc.

N/A

Current Price

$0.99

Market Cap

5.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
AUUD
Founded
1987
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.5M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
SNGX
AUUD
Price
$0.38
$0.99
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
216.1K
3.0M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.51
52 Week High
$3.11
$10.10

Technical Indicators

Market Signals
Indicator
SNGX
AUUD
Relative Strength Index (RSI) 47.76 47.15
Support Level $0.37 $0.92
Resistance Level $0.42 $1.23
Average True Range (ATR) 0.02 0.08
MACD -0.00 0.01
Stochastic Oscillator 36.35 58.70

Price Performance

Historical Comparison
SNGX
AUUD

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About AUUD Auddia Inc.

Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.

Share on Social Networks: